News
SNTI
3.880
+1.04%
0.040
Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment
Barchart · 04/16 08:15
Weekly Report: what happened at SNTI last week (0407-0411)?
Weekly Report · 04/14 10:58
Senti Bio appoints James Trager to Scientific Advisory Board
TipRanks · 04/10 12:50
Press Release: Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.
Dow Jones · 04/10 12:45
Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.
Barchart · 04/10 07:45
Weekly Report: what happened at SNTI last week (0331-0404)?
Weekly Report · 04/07 10:57
Senti Bio Joins Webull Corporate Connect Service Platform
Barchart · 04/07 07:45
Senti Bio To Release SENTI-202 Clinical Data And Novel Logic Gated Gene Circuit Mechanism Of Action In Oral And Poster Presentations At The American Association For Cancer Research Annual Meeting In Chicago April 25-30, 2025
Benzinga · 04/03 13:03
Weekly Report: what happened at SNTI last week (0324-0328)?
Weekly Report · 03/31 11:07
Weekly Report: what happened at SNTI last week (0317-0321)?
Weekly Report · 03/24 10:57
Senti Bio files $300M mixed securities shelf
TipRanks · 03/21 10:15
SENTI BIOSCIENCES : SALES AGREEMENT PROSPECTUS COVERING OFFERING OF UP TO $17.5 MLN COMMON STOCK THAT MAY BE ISSUED UNDER SALES AGREEMENT
Reuters · 03/21 10:13
SENTI BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $300 MLN – SEC FILING
Reuters · 03/21 10:13
Senti Bio files to sell 52.9M shares of common stock for holders
TipRanks · 03/21 10:10
SENTI BIOSCIENCES FILES FOR SHELF OF UP TO 52.9 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 03/21 10:08
Senti Bio Reports Promising Trial Results and Financial Growth
TipRanks · 03/21 04:02
FORM 10-K" This is an annual report filed by Senti Biosciences, Inc. with the Securities and Exchange Commission (SEC) for the fiscal year ended December 31, 2024.
Press release · 03/20 23:40
Senti Biosciences GAAP EPS of -$0.67
Seeking Alpha · 03/20 20:42
Senti Bio reports Q4 EPS (67c), consensus ($3.13)
TipRanks · 03/20 20:10
*Senti Biosciences 4Q Loss/Shr 67c >SNTI
Dow Jones · 03/20 20:02
More
Webull provides a variety of real-time SNTI stock news. You can receive the latest news about Senti Bioscience through multiple platforms. This information may help you make smarter investment decisions.
About SNTI
Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.